Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

248 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First line treatment of chronic phase chronic myeloid leukaemia patients with the generic formulations of imatinib mesylate.
Eskazan AE, Ayer M, Kantarcioglu B, Arica D, Demirel N, Aydin D, Yalniz FF, Elverdi T, Salihoglu A, Ar MC, Ongoren Aydin S, Baslar Z, Aydin Y, Tuzuner N, Ozbek U, Soysal T. Eskazan AE, et al. Among authors: ozbek u. Br J Haematol. 2014 Oct;167(1):139-41. doi: 10.1111/bjh.12937. Epub 2014 May 10. Br J Haematol. 2014. PMID: 24815307 Free article. No abstract available.
The SOCS-1 gene methylation in chronic myeloid leukemia patients.
Hatirnaz O, Ure U, Ar C, Akyerli C, Soysal T, Ferhanoğlu B, Ozçelik T, Ozbek U. Hatirnaz O, et al. Among authors: ozbek u. Am J Hematol. 2007 Aug;82(8):729-30. doi: 10.1002/ajh.20886. Am J Hematol. 2007. PMID: 17315216 Free article.
Effects of imatinib mesylate on renin-angiotensin system (RAS) activity during the clinical course of chronic myeloid leukaemia.
Sayitoglu M, Haznedaroğlu IC, Hatirnaz O, Erbilgin Y, Aksu S, Koca E, Adiguzel C, Bayik M, Akalin I, Gülbas Z, Akay M, Unal A, Kaynar L, Ovali E, Yilmaz M, Yenerel M, Dagdas S, Ozet G, Ar C, Aydin Y, Soysal T, Durgun B, Ozcebe O, Tukun A, Ilhan O, Ozbek U. Sayitoglu M, et al. Among authors: ozbek u. J Int Med Res. 2009 Jul-Aug;37(4):1018-28. doi: 10.1177/147323000903700406. J Int Med Res. 2009. PMID: 19761684 Free article. Clinical Trial.
Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion.
Eskazan AE, Eyice D, Kurt EA, Elverdi T, Yalniz FF, Salihoglu A, Ar MC, Ongoren Aydin S, Baslar Z, Ferhanoglu B, Aydin Y, Tuzuner N, Ozbek U, Soysal T. Eskazan AE, et al. Among authors: ozbek u. Leuk Res. 2014 Jul;38(7):781-7. doi: 10.1016/j.leukres.2014.04.004. Epub 2014 Apr 18. Leuk Res. 2014. PMID: 24832371
Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia.
Tanrikulu Simsek E, Eskazan AE, Cengiz M, Ar MC, Ekizoglu S, Salihoglu A, Gulturk E, Elverdi T, Ongoren Aydin S, Senem Demiroz A, Buyru AN, Baslar Z, Ozbek U, Ferhanoglu B, Aydin Y, Tuzuner N, Soysal T. Tanrikulu Simsek E, et al. Among authors: ozbek u. J Clin Pathol. 2016 Sep;69(9):810-6. doi: 10.1136/jclinpath-2015-203320. Epub 2016 Jan 25. J Clin Pathol. 2016. PMID: 26811428
248 results